PADI4 and Peripheral demyelination: Furthermore, a recent study has demonstrated that compounds designed as potential inhibitors targeting PAD enzymes exhibit significant efficacy in both the MOG35-55 induced EAE mouse model and the cuprizone-mediated demyelination model (65, 90, 91).